HOOKIPA Pharma Inc. (HOOK) Stock Analysis
DELISTED 2026
What happened to HOOKIPA Pharma Inc. (HOOK) stock?
HOOKIPA Pharma Inc. (HOOK) no longer trades on public markets. It was delisted in June 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HOOKIPA Pharma Inc. (HOOK) trades at $1.15. HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for infectious diseases and cancers. Market cap: $14.4M, Sector: Healthcare.
Last analyzed: Jun 14, 2026Analyst Coverage for HOOK: HOOK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HOOK against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
HOOK: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →HOOKIPA Pharma Inc. (HOOK) Healthcare & Pipeline Overview
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical firm specializing in immunotherapies for infectious diseases and cancers, utilizing its proprietary arenavirus platform to target significant unmet medical needs in the healthcare sector.
What Is the Investment Thesis for HOOK?
HOOKIPA Pharma Inc. operates in a high-growth sector, with its proprietary arenavirus platform positioning it favorably within the biotechnology landscape. The company’s lead candidates, HB-201 and HB-202, are currently in clinical trials, which could generate significant value upon successful outcomes. The ongoing Phase II trial of HB-101 for cytomegalovirus-positive kidney transplant patients represents a critical growth catalyst, as positive results could lead to further development and potential commercialization. Additionally, the collaboration with Gilead Sciences for Hepatitis B Virus research adds strategic depth to HOOKIPA's pipeline, potentially opening new revenue streams. However, the company's small market capitalization of $14.4M and negative profit margin of -415.3% present inherent risks, particularly regarding funding and market volatility. Investors should monitor clinical trial results and partnership developments closely, as these factors will significantly influence HOOKIPA's future trajectory.
Based on FMP financials and quantitative analysis
HOOK Key Highlights
Market Cap of $14.4M indicates a small market presence with potential for growth.
- Profit Margin of -415.3% reflects the company's current investment phase and operational challenges.
- Gross Margin of 100.0% highlights the potential for high profitability upon successful product commercialization.
- Beta of 0.83 suggests lower volatility compared to the broader market, indicating relative stability.
- No dividend yield, consistent with the company's focus on reinvesting in clinical development.
Who Are HOOK's Competitors?
HOOK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $146.12 | +1.87% | $181B | 62 |
| BMY Bristol-Myers Squibb Company | $67.01 | +2.35% | $137B | 89 |
| MRNA Moderna, Inc. | $148.60 | +11.46% | $59.0B | — |
| JNJ Johnson & Johnson | $270.83 | +1.29% | $653B | 89 |
| PFE Pfizer Inc. | $27.82 | -1.50% | $159B | 67 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HOOK's Key Strengths?
Innovative proprietary technology platform for immunotherapy.
- Strong pipeline with multiple candidates in clinical development.
- Strategic collaborations enhance research and development capabilities.
- Experienced leadership team with expertise in biotechnology.
What Are HOOK's Weaknesses?
Small market capitalization limits financial flexibility.
- Negative profit margin indicates ongoing investment phase.
- Dependence on successful clinical trial outcomes for future growth.
- Limited product portfolio at this stage of development.
What Could Drive HOOK Stock Higher?
Results from the Phase II trial of HB-101 for cytomegalovirus-positive kidney transplant patients.
- Progress in Phase I/II trials for HB-201 and HB-202 targeting HPV 16-positive cancers.
- Strategic collaboration with Gilead Sciences for Hepatitis B Virus research.
- Potential announcements regarding additional partnerships or funding.
- Development of preclinical candidates HB-300 and HB-700.
What Are the Key Risks for HOOK?
Financial-distress signal — its Altman Z-Score of -13.42 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Dependence on successful clinical trial outcomes for future growth.
- Small market capitalization may limit financial flexibility and increase volatility.
- Regulatory challenges could delay product development and approvals.
- Competition from larger biopharmaceutical companies may impact market share.
What Are the Growth Opportunities for HOOK?
- Growth opportunity 1: HOOKIPA's lead candidate, HB-101, is in a Phase II trial for cytomegalovirus-positive kidney transplant patients. The global market for transplant-related therapies is projected to reach $10 billion by 2027, providing a significant opportunity for HOOKIPA if the trial results are favorable.
- Growth opportunity 2: The ongoing Phase I/II trials for HB-201 and HB-202 targeting HPV 16-positive cancers align with the growing focus on cancer immunotherapy.
- Growth opportunity 3: The collaboration with Gilead Sciences for Hepatitis B Virus research could lead to the development of innovative vaccine products. The global Hepatitis B vaccine market is projected to grow at a CAGR of 5.5%, reaching $3.5 billion by 2027, enhancing HOOKIPA's revenue potential.
- Growth opportunity 4: HOOKIPA's preclinical candidates, such as HB-300 for prostate cancer and HB-700 targeting mutated KRAS, tap into significant unmet medical needs. The prostate cancer therapeutics market is expected to reach $15 billion by 2026, providing a strong incentive for continued development.
- Growth opportunity 5: As HOOKIPA advances its clinical trials and potentially secures regulatory approvals, the company could attract partnerships and investments. The increasing demand for innovative therapies in the biopharmaceutical sector could lead to strategic alliances that enhance HOOKIPA's market presence.
What Opportunities Does HOOK Have?
- Growing demand for innovative therapies in oncology and infectious diseases.
- Potential for partnerships and collaborations to enhance market reach.
- Expansion of preclinical pipeline to address additional therapeutic areas.
- Increasing investment in biotechnology research and development.
What Threats Does HOOK Face?
- Intense competition from established biopharmaceutical companies.
- Regulatory challenges and potential delays in clinical trials.
- Market volatility affecting investor confidence and funding.
- Rapid technological advancements may outpace current capabilities.
What Are HOOK's Competitive Advantages?
- Proprietary arenavirus platform provides a unique technological advantage.
- Strong focus on immunotherapy positions the company in a high-growth market.
- Partnership with Gilead Sciences enhances research capabilities and credibility.
- Ongoing clinical trials demonstrate commitment to advancing innovative therapies.
- Experienced leadership team with a track record in biotechnology.
What Does HOOK Do?
Founded in 2011 and headquartered in New York City, HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative immunotherapies for infectious diseases and various cancers. The company’s proprietary arenavirus platform serves as the foundation for its therapeutic development. HOOKIPA's most advanced program, HB-101, is currently in a randomized, double-blinded Phase II clinical trial, specifically targeting patients awaiting kidney transplantation from cytomegalovirus-positive donors. In the oncology space, the company is progressing with its lead candidates, HB-201 and HB-202, which are undergoing Phase I/II clinical trials aimed at treating human papillomavirus 16-positive cancers. Furthermore, HOOKIPA is expanding its preclinical pipeline with promising candidates such as HB-300 for prostate cancer and HB-700, which targets mutated KRAS in pancreatic, colorectal, and lung cancers. The company has also established a strategic collaboration with Gilead Sciences, Inc., focusing on preclinical research to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. This partnership leverages HOOKIPA's advanced replicating and non-replicating technology platforms, enhancing its research capabilities and market position. With a dedicated team of 82 employees, HOOKIPA Pharma Inc. is committed to addressing critical healthcare challenges through its innovative therapeutic approaches.
What Products and Services Does HOOK Offer?
- Develops immunotherapies for infectious diseases and cancers.
- Utilizes a proprietary arenavirus platform for therapeutic advancements.
- Conducts clinical trials for lead candidates targeting specific cancers.
- Collaborates with other biopharmaceutical companies for research.
- Focuses on addressing unmet medical needs in healthcare.
- Maintains a preclinical pipeline for future therapeutic development.
How Does HOOK Make Money?
- Generates revenue through potential commercialization of successful therapies.
- Engages in strategic collaborations to enhance research capabilities.
- Attracts investment for clinical trial funding and operational growth.
- Focuses on innovative drug development to meet market demands.
- Utilizes proprietary technology platforms to differentiate its offerings.
What Industry Does HOOK Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the fields of immunotherapy and personalized medicine. The competitive landscape includes major players focusing on similar therapeutic areas, necessitating continuous innovation and effective clinical trial management to maintain a competitive edge.
Who Are HOOK's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients with unmet medical needs in infectious diseases and cancers.
- Pharmaceutical companies looking for strategic partnerships.
- Investors interested in biotechnology and healthcare advancements.
- Research institutions collaborating on therapeutic development.
Forward Outlook
Wall Street analysts project HOOKIPA Pharma Inc. revenue of about $1.0M for fiscal 2026, with EPS near $-2.14.
Key Financial Metrics
Return on assets is -80.0%, showing how much profit it generates from its asset base. A current ratio of 3.93 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
HOOKIPA Pharma Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.42 places it in the distress zone, a signal of elevated financial risk.
HOOK Valuation & Market Position
With a $14.4M market cap, HOOKIPA Pharma Inc. sits in the micro-cap segment of the market.
HOOK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative proprietary technology platform for immunotherapy.
- Strong pipeline with multiple candidates in clinical development.
- Strategic collaborations enhance research and development capabilities.
- Experienced leadership team with expertise in biotechnology.
Bear Case
- Small market capitalization limits financial flexibility.
- Negative profit margin indicates ongoing investment phase.
- Dependence on successful clinical trial outcomes for future growth.
- Limited product portfolio at this stage of development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
HOOK Latest News
No recent news available for HOOK.
Leadership: Malte Peters
CEO
Malte Peters has extensive experience in the biopharmaceutical industry, having held various leadership roles in research and development. He has a strong background in immunology and has been instrumental in advancing innovative therapeutic solutions. His educational credentials include a PhD in Molecular Biology, equipping him with the necessary expertise to lead HOOKIPA Pharma Inc. in its mission to develop groundbreaking therapies.
Track Record: Under Malte Peters' leadership, HOOKIPA has made significant strides in its clinical programs, advancing multiple candidates through various stages of development. His strategic vision has facilitated key partnerships, such as the collaboration with Gilead Sciences, enhancing the company's research capabilities and market positioning.
HOOK OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements for major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and higher volatility, making them riskier investments. Companies in this tier often have less stringent reporting requirements, which can impact transparency.
- OTC Tier: OTC Other
- Higher volatility associated with OTC stocks compared to major exchanges.
- Limited financial reporting may obscure the company's true financial health.
- Potential for lower liquidity, making it difficult to execute large trades.
- Increased susceptibility to market manipulation due to lower trading volumes.
- Review recent clinical trial results and updates.
- Assess the company's financial health through available reports.
- Evaluate the impact of partnerships on research and development.
- Monitor regulatory developments related to ongoing trials.
- Investigate the competitive landscape and market positioning.
- Established partnerships with reputable companies like Gilead Sciences.
- Presence of an experienced leadership team with industry expertise.
- Ongoing clinical trials demonstrating commitment to innovation.
HOOKIPA Pharma Inc. Healthcare Stock: Key Questions Answered
What happened to HOOKIPA Pharma Inc. (HOOK) stock?
HOOKIPA Pharma Inc. (HOOK) no longer trades on public markets. It was delisted in June 2026. The figures below are historical and are not a current quote.
Can I still buy HOOK shares?
No. HOOK stopped trading on public markets in June 2026, so the shares are not available through a broker. Anything you see quoted for HOOK elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before HOOK stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to HOOKIPA Pharma Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does HOOKIPA Pharma Inc. do?
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for infectious diseases and various cancers. Utilizing its proprietary arenavirus platform, the company is advancing multiple clinical programs, including HB-101 for cytomegalovirus-positive kidney transplant patients and HB-201 and HB-202 for HPV 16-positive cancers.
What is HOOKIPA Pharma Inc.'s drug pipeline status?
HOOKIPA Pharma Inc. has several candidates in various stages of clinical development. The most advanced program, HB-101, is currently in a Phase II trial, while HB-201 and HB-202 are in Phase I/II trials. Additionally, the company has preclinical candidates like HB-300 and HB-700 targeting prostate cancer and mutated KRAS, respectively.
What are the main risks for HOOK?
HOOKIPA Pharma Inc. faces several risks, including dependence on the successful outcomes of clinical trials, which are critical for future growth. The company's small market capitalization may limit its financial flexibility and expose it to higher volatility. Additionally, regulatory challenges could delay product development and approvals, while competition from larger biopharmaceutical companies poses a threat to its market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available reports and may be subject to change.